TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 31286397

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (loading dose of 1 μg kg-1 followed by 0.5 μg kg-1 h-1)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Morphine sulfate (bolus 0.08 mg kg-1 followed by a saline infusion)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Comparison of intraoperative morphine consumption
Number of subjects: 60
Study: 28012050

Group type: EXPERIMENTAL
Intervention: Bioresorbable vascular scaffold (BVS)
Number of subjects: 501

Group type: COMPARATOR
Intervention: Everolimus-eluting metallic stent (EES)
Number of subjects: 501

Group type: EXPERIMENTAL
Intervention: Bioresorbable vascular scaffold (BVS) after subtraction of theoretical device volume
Number of subjects: 501

Group type: COMPARATOR
Intervention: Everolimus-eluting metallic stent (EES) after subtraction of theoretical device volume
Number of subjects: 501

Group type: EXPERIMENTAL
Intervention: Bioresorbable vascular scaffold (BVS) after correction for radiofrequency backscattering
Number of subjects: 501

Group type: COMPARATOR
Intervention: Everolimus-eluting metallic stent (EES) after correction for radiofrequency backscattering
Number of subjects: 501

Group type: EXPERIMENTAL
Intervention: Bioresorbable vascular scaffold (BVS) after correction for echogenicity
Number of subjects: 501

Group type: COMPARATOR
Intervention: Everolimus-eluting metallic stent (EES) after correction for echogenicity
Number of subjects: 501
Study: 25972074

Group type: EXPERIMENTAL
Intervention: Virtual reality distraction
Number of subjects: 65

Group type: COMPARATOR
Intervention: Standard distraction methods
Number of subjects: 65
Study: 22517036

Group type: EXPERIMENTAL
Intervention: Higher parenteral amino acid intakes (4 g kg(‐1) per day)
Number of subjects: 115

Group type: COMPARATOR
Intervention: Standard parenteral amino acid intakes (3 g kg(‐1) per day)
Number of subjects: 115
Study: 22141230

Group type: EXPERIMENTAL
Intervention: High precious alloy + low fusing porcelain (group A)
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Zirconia crowns (group B)
Number of subjects: 49
Study: 19543958

Group type: EXPERIMENTAL
Intervention: CD25(+) regulatory T cells from SIT patients
Number of subjects: 0

Group type: COMPARATOR
Intervention: CD25(+) regulatory T cells from controls
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: CD25(+) regulatory T cells from SIT patients and controls (when cultured together)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: CD25(neg) and CD25(pos) T cells from SIT patients and controls (when cultured together)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: SIT patients
Number of subjects: 0
Study: 17221216

Group type: EXPERIMENTAL
Intervention: Goeckerman's therapy (GT)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Healthy blood donors (control)
Number of subjects: 44
Study: 12582020

Group type: EXPERIMENTAL
Intervention: High-dose aliretinoin (50 mg)
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: Low-dose aliretinoin (25 mg)
Number of subjects: 114

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 114
Study: 10918204

Group type: EXPERIMENTAL
Intervention: Fenretinide (4-HPR)
Number of subjects: 0
Study: 9171752

Group type: EXPERIMENTAL
Intervention: High-dose bolus tPA (three doses of 5 mg over 30 min, then 3.5 mg/h for up to 4 h, then 0.5-1.0 mg/h)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Low-dose tPA (0.5-1.0 mg/h)
Number of subjects: 100
Study: 9114905

Group type: EXPERIMENTAL
Intervention: 10 mg benazepril
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: 10 mg enalapril
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study: 3511937

Group type: EXPERIMENTAL
Intervention: Indomethacin (50 mg acute treatment)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Indomethacin (25 mg twice daily for 7 days chronic treatment)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Indomethacin (acute and chronic treatments)
Number of subjects: 0
Study: 29705457

Group type: EXPERIMENTAL
Intervention: Relaxation techniques (Benson muscle relaxation)
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Inhalation of 5% lavender essential oil (2 drops)
Number of subjects: 105

Group type: COMPARATOR
Intervention: Control group (regular healthcare actions)
Number of subjects: 105
Study: 27206122

Group type: EXPERIMENTAL
Intervention: Job strain (high strain jobs)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Low strain jobs
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Renin angiotensin system antagonists (RASA)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Statins
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: All medication classes combined
Number of subjects: 0
Study: 24646861

Group type: EXPERIMENTAL
Intervention: PA21 (sucroferric oxyhydroxide) 1.0-3.0 g per day
Number of subjects: 707

Group type: COMPARATOR
Intervention: Sevelamer carbonate 4.8-14.4 g per day
Number of subjects: 707

Group type: EXPERIMENTAL
Intervention: PA21 maintenance dose
Number of subjects: 707

Group type: COMPARATOR
Intervention: Low dose (250 mg per day)
Number of subjects: 707

Group type: EXPERIMENTAL
Intervention: PA21
Number of subjects: 707

Group type: COMPARATOR
Intervention: Sevelamer
Number of subjects: 707
Study: 22329470

Group type: EXPERIMENTAL
Intervention: Inhaled loxapine 5 mg
Number of subjects: 314

Group type: EXPERIMENTAL
Intervention: Inhaled loxapine 10 mg
Number of subjects: 314

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 314
Study: 20578931

Group type: EXPERIMENTAL
Intervention: OROS methylphenidate (OROS MPH) 54 mg or greater
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: OROS methylphenidate (OROS MPH)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Weight-adjusted dose of OROS MPH
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Absolute dose of OROS MPH
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Baseline symptom severity
Number of subjects: 100
Study: 18626046

Group type: COMPARATOR
Intervention: Graduated compression stockings for 7 days (660 patients)
Number of subjects: 1761

Group type: EXPERIMENTAL
Intervention: LMWH (nadroparin, 3800 anti-Xa IU) for 7 days (657 patients)
Number of subjects: 1761

Group type: EXPERIMENTAL
Intervention: LMWH (nadroparin, 3800 anti-Xa IU) for 14 days (444 patients)
Number of subjects: 1761
Study: 15755222

Group type: EXPERIMENTAL
Intervention: Appraisal of novelty (factors related to unfamiliarity and complexity)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Appraisal of coping potential (the ability to understand the new, complex thing)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Measured and manipulated appraisals
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Self-reports, forced-choice, behavioral measures
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Appraisal structure specific to interest
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Appraisals predicted interest beyond relevant traits (curiosity, openness)
Number of subjects: 0
Study: 12698305

Group type: EXPERIMENTAL
Intervention: Retigabine (RGB) 200 mg single oral doses on day 1 and day 7, and Lamotrigine (LTG) 25 mg o.i.d. on days 3-8
Number of subjects: 29

Group type: COMPARATOR
Intervention: Lamotrigine (LTG) 200 mg single oral doses on day 1 and day 17, and up-titrated to 300 mg RGB b.i.d. on days 6-20
Number of subjects: 29
Study: 10085547

Group type: EXPERIMENTAL
Intervention: Participants who received a sympathetic paper
Number of subjects: 117

Group type: EXPERIMENTAL
Intervention: Participants who received an unsympathetic paper
Number of subjects: 117

Group type: EXPERIMENTAL
Intervention: Participants who received a paper incongruent with their beliefs
Number of subjects: 117

Group type: EXPERIMENTAL
Intervention: Participants who received a paper congruent with their beliefs
Number of subjects: 117
Study: 8933494

Group type: EXPERIMENTAL
Intervention: Running training (3 d.wk‐1, 10‐40 min/session, 80‐90% of exercise specific maximal heart rate)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: In-line skating training (3 d.wk‐1, 10‐40 min/session, 80‐90% of exercise specific maximal heart rate)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Control group (no systematic training)
Number of subjects: 42
Study: 1745707

Group type: EXPERIMENTAL
Intervention: Caffeine (1, 2, 3, and 4 mg/kg body weight)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 6127040

Group type: EXPERIMENTAL
Intervention: Midazolam 15 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Flunitrazepam 2 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 31307925

Group type: EXPERIMENTAL
Intervention: Bariatric surgery in NAFLD patients
Number of subjects: 302306

Group type: COMPARATOR
Intervention: Bariatric surgery in non-NAFLD patients
Number of subjects: 302306
Study: 30135019

Group type: EXPERIMENTAL
Intervention: Revascularization (by percutaneous coronary intervention or coronary artery bypass graft surgery)
Number of subjects: 9326

Group type: EXPERIMENTAL
Intervention: Revascularization
Number of subjects: 9326

Group type: COMPARATOR
Intervention: No revascularization
Number of subjects: 9326
Study: 26606271

Group type: COMPARATOR
Intervention: 1.5 g·kg⁻¹·h⁻¹ glucose (GLU)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: 1.2 g·kg⁻¹·h⁻¹ glucose + 0.3 g·kg⁻¹·h⁻¹ fructose (GLU + FRU)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: 0.9 g·kg⁻¹·h⁻¹ glucose + 0.6 g·kg⁻¹·h⁻¹ sucrose (GLU + SUC)
Number of subjects: 14
Study: 25287825

Group type: EXPERIMENTAL
Intervention: Real-time quantitative polymerase chain reaction (RQ‐PCR) for minimal residual disease (MRD) monitoring
Number of subjects: 110
Study: 22296837

Group type: EXPERIMENTAL
Intervention: Logistic regression models using predictors: age, ISS, GCS, SBP, RR.
Number of subjects: 10210

Group type: EXPERIMENTAL
Intervention: Logistic regression models applied to Khon Kaen data.
Number of subjects: 10210
Study: 20824720

Group type: EXPERIMENTAL
Intervention: gemcitabine/erlotinib
Number of subjects: 569

Group type: COMPARATOR
Intervention: gemcitabine/placebo
Number of subjects: 569
Study: 18277739

Group type: COMPARATOR
Intervention: Colgate Wave manual toothbrush + Colgate Total dentifrice (0.3% triclosan/copolymer dentifrice)
Number of subjects: 179

Group type: EXPERIMENTAL
Intervention: Wave + Total + Listerine (essential oils rinse)
Number of subjects: 179

Group type: EXPERIMENTAL
Intervention: Oral-B CrossAction manual toothbrush + Crest Pro-Health dentifrice (0.454% stannous fluoride/sodium hexametaphosphate)
Number of subjects: 179

Group type: EXPERIMENTAL
Intervention: CrossAction + Pro-Health dentifrice + Crest Pro-Health Rinse (0.07% cetylpyridinium chloride rinse)
Number of subjects: 179

Group type: EXPERIMENTAL
Intervention: Oral-B ProfessionalCare Series 8000 power toothbrush + Pro-Health dentifrice
Number of subjects: 179

Group type: EXPERIMENTAL
Intervention: ProfessionalCare power brush + Pro-Health dentifrice + Oral-B Hummingbird power flosser
Number of subjects: 179
Study: 16124951

Group type: EXPERIMENTAL
Intervention: Enoxaparin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Unfractionated heparin (UFH)
Number of subjects: 0
Study: 14648807

Group type: EXPERIMENTAL
Intervention: Atorvastatin 40 mg/day
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 10577995

Group type: EXPERIMENTAL
Intervention: Candesartan cilexetil 16 mg
Number of subjects: 844

Group type: EXPERIMENTAL
Intervention: Candesartan cilexetil 4 mg, 8 mg, 16 mg
Number of subjects: 844

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 844

Group type: EXPERIMENTAL
Intervention: Candesartan cilexetil (all doses)
Number of subjects: 844
Study: 8767620

Group type: EXPERIMENTAL
Intervention: defibrotide (400 mg bid)
Number of subjects: 100

Group type: COMPARATOR
Intervention: heparan-sulfate (40 mg bid)
Number of subjects: 100
Study: 1939901

Group type: EXPERIMENTAL
Intervention: 10‐ms tones at frequencies of 0.25, 1, 8, or 14 kHz and levels of 30, 60, or 90 dB SPL
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: 500‐ms stimuli: a 1‐kHz tone at 90 dB SPL and broadband noise at 63 dB SPL
Number of subjects: 5
Study: 7036914

Group type: EXPERIMENTAL
Intervention: Spironolactone (group B, n = 11)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Potassium supplements (group A, n = 10)
Number of subjects: 21
Study: 30941817

Group type: EXPERIMENTAL
Intervention: DASH diet
Number of subjects: 85

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 85
Study: 28760277

Group type: EXPERIMENTAL
Intervention: Patient Decision Aid (PDA)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Standard information only (Control)
Number of subjects: 72
Study: 26502850

Group type: EXPERIMENTAL
Intervention: Capecitabine maintenance therapy (oral capecitabine 1,250 mg/m2 twice daily on days 1-14 every 3 weeks)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Control group (not specified treatment)
Number of subjects: 72
Study: 23081843

Group type: EXPERIMENTAL
Intervention: Gentamicin (10 mg) added to contrast medium
Number of subjects: 114

Group type: COMPARATOR
Intervention: Distilled water added to contrast medium (Control)
Number of subjects: 114
Study: 22919877

Group type: EXPERIMENTAL
Intervention: Intravenous pantoprazole (PPI) 80 mg + 8 mg/h for 72 hours
Number of subjects: 122
Study: 20026882

Group type: EXPERIMENTAL
Intervention: WMAS (standing wall stretching with medial arch support)
Number of subjects: 30

Group type: COMPARATOR
Intervention: WOMAS (standing wall stretching without medial arch support)
Number of subjects: 30
Study: 17536226

Group type: EXPERIMENTAL
Intervention: Indapamide
Number of subjects: 40

Group type: COMPARATOR
Intervention: Enalapril
Number of subjects: 40

Group type: COMPARATOR
Intervention: Metoprolol
Number of subjects: 40

Group type: COMPARATOR
Intervention: Amlodipine
Number of subjects: 40
Study: 11094036

Group type: EXPERIMENTAL
Intervention: Intra-arterial infusion of [(3)H]L-arginine (100 nCi/min)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: [(3)H]L-arginine uptake by peripheral blood mononuclear cells (PBMCs)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: mRNA expression for the cationic amino acid transporter CAT-1
Number of subjects: 0
Study: 8985768

Group type: EXPERIMENTAL
Intervention: Intranasal mupirocin
Number of subjects: 20

Group type: COMPARATOR
Intervention: Nasal carriage of Staphylococcus aureus
Number of subjects: 20
Study: 1618242

Group type: EXPERIMENTAL
Intervention: Sustained-release nicardipine 45-60 mg/d
Number of subjects: 42

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42
Study: 6367689

Group type: EXPERIMENTAL
Intervention: Antidepressant drug treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 30549321

Group type: EXPERIMENTAL
Intervention: Tailored repositioning and turning and repositioning system
Number of subjects: 227

Group type: EXPERIMENTAL
Intervention: Turning and repositioning system
Number of subjects: 227

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 227
Study: 29342393

Group type: COMPARATOR
Intervention: Cytoreductive surgery without HIPEC
Number of subjects: 245

Group type: EXPERIMENTAL
Intervention: Cytoreductive surgery with HIPEC
Number of subjects: 245

Group type: EXPERIMENTAL
Intervention: Both groups (surgery and surgery-plus-HIPEC)
Number of subjects: 245
Study: 27230831

Group type: EXPERIMENTAL
Intervention: Acute stress induction
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 0
Study: 24248803

Group type: EXPERIMENTAL
Intervention: HIV prevention intervention (guided by Social Action Theory)
Number of subjects: 9678

Group type: COMPARATOR
Intervention: Attention-matched control intervention (focused on prevention of relationship violence)
Number of subjects: 9678

Group type: EXPERIMENTAL
Intervention: Community-level outcomes
Number of subjects: 9678
Study: 21996087

Group type: EXPERIMENTAL
Intervention: Immunohistochemistry (IHC) for ERCC1
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Immunohistochemistry (IHC) for TUBB3
Number of subjects: 33

Group type: COMPARATOR
Intervention: qRT-PCR for ERCC1, BRCA1, RRM1, TUBB3
Number of subjects: 33
Study: 21090829

Group type: EXPERIMENTAL
Intervention: Bisphosphonates (specifically zoledronic acid)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Observational studies (cohort and case-control)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Meta-analyses
Number of subjects: 0
Study: 17929555

Group type: EXPERIMENTAL
Intervention: Growth hormone (GH) and aspirin; n = 20
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group without GH or aspirin; n = 20
Number of subjects: 40
Study: 16261109

Group type: EXPERIMENTAL
Intervention: Corticosteroids
Number of subjects: 0

Group type: COMPARATOR
Intervention: Saline (Control)
Number of subjects: 0
Study: 12131260

Group type: EXPERIMENTAL
Intervention: 20 g/d bovine colostrum + 40 g whey protein concentrate (wpc)
Number of subjects: 42
Study: 10068161

Group type: EXPERIMENTAL
Intervention: Disclosure condition
Number of subjects: 80

Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 80
Study: 7675613

Group type: EXPERIMENTAL
Intervention: Normal game condition
Number of subjects: 40

Group type: COMPARATOR
Intervention: Reverse control condition
Number of subjects: 40
Study: 2404650

Group type: EXPERIMENTAL
Intervention: iopentol 300 mg I/ml
Number of subjects: 300

Group type: COMPARATOR
Intervention: iohexol 300 mg I/ml
Number of subjects: 300
Study: 31290747

Group type: EXPERIMENTAL
Intervention: 1-day intravenous antibiotics (cefmetazole and metronidazole)
Number of subjects: 176

Group type: COMPARATOR
Intervention: 4-day intravenous and oral antibiotics (cefmetazole and metronidazole)
Number of subjects: 176

Group type: EXPERIMENTAL
Intervention: 1-day intravenous antibiotics
Number of subjects: 176

Group type: COMPARATOR
Intervention: 4-day intravenous and oral antibiotics
Number of subjects: 176
Study: 28850408

Group type: EXPERIMENTAL
Intervention: Local infiltration analgesia (LIA)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Femoral nerve block (FNB)
Number of subjects: 56
Study: 26070468

Group type: EXPERIMENTAL
Intervention: Individualized intensive staged-based nutrition education by a dedicated renal dietitian
Number of subjects: 394

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 394

Group type: COMPARATOR
Intervention: Nutrition education from general hospital dietitians
Number of subjects: 394
Study: 23471413

Group type: EXPERIMENTAL
Intervention: JNJ‐39588146 (15 ng/kg/min)
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: JNJ‐39588146 (30 ng/kg/min)
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: JNJ‐39588146 (any dose)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 62
Study: 21290111

Group type: EXPERIMENTAL
Intervention: PCL-retaining (PCLR) prosthesis
Number of subjects: 108

Group type: COMPARATOR
Intervention: PCL-sacrificing (PCLS) prosthesis
Number of subjects: 108
Study: 20803860

Group type: EXPERIMENTAL
Intervention: 0.5% levobupivacaine 7.5 mg (Group I)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: 0.5% levobupivacaine 10 mg (Group II)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: 0.5% levobupivacaine 12.5 mg (Group III)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: 0.5% levobupivacaine 15 mg (Group IV)
Number of subjects: 80
Study: 17956835

Group type: EXPERIMENTAL
Intervention: didanosine/stavudine (n = 8)
Number of subjects: 19

Group type: COMPARATOR
Intervention: didanosine/lamivudine plus nevirapine (n = 7)
Number of subjects: 19

Group type: COMPARATOR
Intervention: didanosine/lamivudine plus ritonavir-boosted saquinavir (n = 4)
Number of subjects: 19
Study: 16400889

Group type: EXPERIMENTAL
Intervention: Home-based education, cockroach and rodent extermination, mattress and pillow encasings, high-efficiency particulate air cleaner
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control group (treated at the end of the 1-year trial)
Number of subjects: 100
Study: 12507680

Group type: EXPERIMENTAL
Intervention: Multicomponent intervention (Regulatory enforcement, Education, Peer influence)
Number of subjects: 68

Group type: COMPARATOR
Intervention: Control pharmacies
Number of subjects: 68
Study: 9585287

Group type: EXPERIMENTAL
Intervention: Clonidine 5 microg/kg (CLON)
Number of subjects: 88

Group type: COMPARATOR
Intervention: No premedication (CONT)
Number of subjects: 88
Study: 7707407

Group type: COMPARATOR
Intervention: Standard radiation therapy (60 Gy delivered at 2 Gy per fraction, 5 days a week, over a 6-week period)
Number of subjects: 452

Group type: EXPERIMENTAL
Intervention: Induction chemotherapy (cisplatin 100 mg/m2 on days 1 and 29, vinblastine 5 mg/m2 per week for 5 weeks) followed by standard radiation therapy (starting on day 50)
Number of subjects: 452

Group type: EXPERIMENTAL
Intervention: Hyperfractionated radiation therapy (69.6 Gy delivered at 1.2 Gy per fraction twice daily)
Number of subjects: 452
Study: 2543337

Group type: EXPERIMENTAL
Intervention: Hypertonic saline (1.8% NaCl)
Number of subjects: 20

Group type: COMPARATOR
Intervention: 0.9% NaCl (NS)
Number of subjects: 20
Study: 344086

Group type: EXPERIMENTAL
Intervention: Serenace
Number of subjects: 25

Group type: COMPARATOR
Intervention: Chlorpromazine
Number of subjects: 25
Study: 31491583

Group type: EXPERIMENTAL
Intervention: CBT + BA + CM
Number of subjects: 120

Group type: COMPARATOR
Intervention: CBT + BA
Number of subjects: 120
Study: 27255407

Group type: EXPERIMENTAL
Intervention: Inex Pediculicide Soap®
Number of subjects: 45

Group type: COMPARATOR
Intervention: Paranix®
Number of subjects: 45
Study: 25351561

Group type: EXPERIMENTAL
Intervention: 50 mg of daidzein
Number of subjects: 165

Group type: EXPERIMENTAL
Intervention: 50 mg of genistein
Number of subjects: 165

Group type: COMPARATOR
Intervention: 10 g of soy protein plus no addition
Number of subjects: 165
Study: 23154216

Group type: COMPARATOR
Intervention: Modification of school cafeteria environment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Cafeteria modification program
Number of subjects: 0
Study: 21624774

Group type: EXPERIMENTAL
Intervention: Total Sleep Deprivation (T-SD) for 2 consecutive nights
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: REM Sleep Deprivation (REM-SD) for 4 consecutive nights
Number of subjects: 28

Group type: COMPARATOR
Intervention: Control (CTRL) group
Number of subjects: 28
Study: 19322731

Group type: EXPERIMENTAL
Intervention: Mindfulness-Based Stress Reduction (MBTC)
Number of subjects: 459

Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 459
Study: 17041809

Group type: EXPERIMENTAL
Intervention: Combined endurance and strength training for 4 months after initial 4 months of training
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (ceased training after 4 months)
Number of subjects: 20
Study: 12919161

Group type: EXPERIMENTAL
Intervention: Milk supplementation during pregnancy and childhood
Number of subjects: 951